Whoop Expands into Comprehensive Health Platforms

Whoop, a company known for its screen-free fitness band, has been expanding its presence in the broader healthcare space. The latest development in this direction is the announcement that its blood-testing service, Whoop Advanced Labs, is now available without requiring a Whoop membership.

Source: lifehacker.com

This move is part of Whoop’s strategy to grow beyond ‘wearables’ into comprehensive health platforms. Advanced Labs is a direct-to-consumer product that allows individuals to purchase blood tests without being tied to a membership. The service is powered by Quest Diagnostics and covers various aspects of health, including cardiovascular, metabolic, hormonal, and inflammatory health.

The process of using Whoop Advanced Labs is straightforward. After purchasing a test, which starts at around $150, individuals can schedule a blood draw through the Whoop app. The blood draw can be conducted at a local clinic, and in the future, mobile at-home draws will be available in select regions. Each test is ordered by a licensed healthcare provider, and the resulting report is reviewed by a licensed clinician before being made available in the app. The report includes clear, actionable guidance to help individuals understand their results.

The addition of the Galleri test, which screens for multi-cancer early detection, is another significant development. This test uses a single blood draw to identify a signal shared across more than 50 cancer types. It’s essential to note that this test detects a signal suggesting cancer may be present, not a diagnosis. The Galleri test is meant to supplement standard screenings recommended by doctors, not replace them.

It’s worth noting that Advanced Labs is not currently covered by insurance, although purchases may qualify for HSA or FSA reimbursement. It’s crucial for individuals to confirm with their plan administrator before making a purchase.

The expansion of Whoop Advanced Labs without a membership requirement widens the pool of potential users. However, it’s essential to consider whether individuals buying these tests understand what they’re signing up for and have a plan for handling unexpected findings. Comprehensive biomarker panels can provide valuable information, but they can also generate borderline or ambiguous results that may create worry without a clear next step.

Reviewing multiple biomarkers can increase the likelihood of encountering results outside a ‘normal’ range purely by chance. Moreover, not every flagged number translates into meaningful medical action. When it comes to multi-cancer early detection tests like Galleri, consumers should be prepared to discuss false positives, false negatives, and the appropriate course of action with a human medical professional.

As wearable companies continue to edge into territory traditionally belonging to doctor’s offices, it’s essential to watch this development closely. Whoop’s decision to make its blood-testing service available without a membership requirement is a significant step towards creating comprehensive health platforms.